Trials / Unknown
UnknownNCT03769285
Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: A Pilot, Placebo-controlled, Randomized Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Women's College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A common long-term side effect of anti-rejection (immunosuppressant) medications is skin cancer. This pilot clinical trial evaluates the feasibility of conducting a larger pivotal trial to examine the efficacy and safety of nicotinamide for prevention of keratinocyte carcinoma in solid organ transplant recipients. This pilot trial will transition into the pivotal trial if all feasibility targets are met.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nicotinamide | Oral nicotinamide (500 mg) twice daily for at least 52 weeks |
| DRUG | Placebo oral capsule | Matching placebo taken twice daily for at least 52 weeks |
Timeline
- Start date
- 2018-12-03
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2018-12-07
- Last updated
- 2023-04-06
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03769285. Inclusion in this directory is not an endorsement.